spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Cytokine 

 HSMN NewsFeed - 17 Jun 2026
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Mar 2026
VST BIO Corporation Announces Series A Financing to Advance VB-001 and Adds William Sessa to Board of Directors
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 26 Feb 2026
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
Regenerative Medicine Neurology Venture Capital
 HSMN NewsFeed - 25 Feb 2026
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Feb 2026
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
Regenerative Medicine Neurology Venture Capital
 HSMN NewsFeed - 20 Aug 2025
CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR
Devices FDA
 HSMN NewsFeed - 3 Jul 2025
Novartis Provides Update on Phase III GCAptAIN Study of Cosentyx(R) in Giant Cell Arteritis (GCA)
Biopharmaceuticals
 HSMN NewsFeed - 27 May 2025
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn(R) Phase 3b ALS Clinical Trials
Regenerative Medicine Neurology
 HSMN NewsFeed - 14 Apr 2025
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
Devices Personnel
 HSMN NewsFeed - 10 Apr 2025
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 7 Mar 2025
Zimmer Biomet Receives FDA Clearance for Persona(R) Revision SoluTion(TM) Femur
Devices Orthopaedic FDA
 HSMN NewsFeed - 12 Feb 2025
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 16 Jan 2025
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX(R) (bimekizumab-bkzx)
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 25 Oct 2024
Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 23 Sep 2024
UCB Announces U.S. FDA Approvals for BIMZELX(R) (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jul 2024
Alltrna Announces Updates to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Apr 2024
Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Apr 2024
NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jan 2024
NeoImmuneTech Welcomes a New President for its Development and Business
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Nov 2023
FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Oct 2023
FDA Approves Novartis Cosentyx(R) as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Jun 2023
VIVEX Biologics, Inc. Launches New CYGNUS(R) Dual Amniotic Allograft
Devices Wound Care Product Launch
 HSMN NewsFeed - 27 Mar 2023
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn(R) for the Treatment of ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 19 Jan 2023
Halia Therapeutics Appoints Former Amgen Executive, Margit M. Janát-Amsbury, MD, Ph.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Dec 2022
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 10 Nov 2022
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 2 Nov 2022
'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals
Devices
 HSMN NewsFeed - 19 Sep 2022
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI(R)) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 15 Sep 2022
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn(R) Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
Regenerative Medicine Neurology
 HSMN NewsFeed - 1 Jun 2022
CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries
Devices Distribution
 HSMN NewsFeed - 2 May 2022
CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany
Devices Group Purchasing
 HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Apr 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE(TM) Molecule
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Jan 2022
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 27 Dec 2021
FDA Authorizes Further NurOwn(R) Dosing Under Expanded Access Program
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 22 Dec 2021
Sorriso Pharmaceuticals Launches with $31 Million to Develop Novel Class of Orally Delivered Cytokine Antibodies to Treat Inflammatory Conditions
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Dec 2021
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 20 Dec 2021
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb(R) in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
Devices
 HSMN NewsFeed - 17 Dec 2021
OncoSec Announces Changes to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2021
Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Nov 2021
SeaStar Medical Presents Data from SCD 005 Clinical Study at the American Society of Nephrology (ASN) Kidney Week 2021 Annual Meeting
Devices
 HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals
 HSMN NewsFeed - 16 Sep 2021
Sutro Biopharma Announces Expansion of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Sep 2021
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR(TM) Antithrombotic Removal System During Urgent Cardiothoracic Surgery
Devices Surgery FDA
 HSMN NewsFeed - 30 Aug 2021
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Aug 2021
European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 18 Aug 2021
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Aug 2021
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 13 Aug 2021
Rigel Pharmaceuticals Provides Update on COVID-19 Program
Biopharmaceuticals
 HSMN NewsFeed - 12 Aug 2021
Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR(TM) Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery
Devices FDA
 HSMN NewsFeed - 9 Aug 2021
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Aug 2021
SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jul 2021
SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jul 2021
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jul 2021
Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2021
Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19
Regenerative Medicine Licensing
 HSMN NewsFeed - 17 May 2021
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 14 Apr 2021
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse(TM)" for the Treatment of Solid Tumors
Devices Oncology Regulatory
 HSMN NewsFeed - 31 Mar 2021
CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Mar 2021
Bioniz Therapeutics Appoints Dr. Alexandre Kaoukhov to Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Mar 2021
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Feb 2021
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
Biopharmaceuticals Licensing
 HSMN NewsFeed - 10 Feb 2021
Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung Disease
Regenerative Medicine Acquisitions
 HSMN NewsFeed - 2 Feb 2021
OncoSec Strengthens Management Team With Two New Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jan 2021
Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Jan 2021
CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing
Devices Personnel
 HSMN NewsFeed - 7 Jan 2021
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Dec 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2020
BrainStorm Announces NurOwn(R) Expanded Access Program
Regenerative Medicine Neurology Product Launch
 HSMN NewsFeed - 23 Nov 2020
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
Regenerative Medicine Neurology
 HSMN NewsFeed - 23 Nov 2020
Innovent Announces NMPA Granted New Indication Approval for SULINNO(R) (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Nov 2020
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Nov 2020
BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study
Regenerative Medicine Neurology
 HSMN NewsFeed - 10 Nov 2020
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Nov 2020
Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2020
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Sep 2020
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100(TM) and Selection of Commercial Partners
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2020
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Aug 2020
Werewolf Therapeutics Appoints Business Leader, Ellen Lubman, as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Aug 2020
FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 31 Jul 2020
CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development
Devices
 HSMN NewsFeed - 28 Jul 2020
CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data
Devices
 HSMN NewsFeed - 24 Jul 2020
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 20 Jul 2020
FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients with Moderate To Severe Covid-19
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jul 2020
Imvax Inc. Raises $112 Million in Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Jun 2020
CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise
Devices Product Launch
 HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
Regenerative Medicine Neurology
 HSMN NewsFeed - 4 Jun 2020
Mylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
Biopharmaceuticals Generics Regulatory
 HSMN NewsFeed - 3 Jun 2020
Novo Ventures Leads US$55M Series B Investment in NodThera
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Jun 2020
Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 May 2020
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 21 May 2020
Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 May 2020
CytoSorb(R) is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
Devices Regulatory
 HSMN NewsFeed - 8 May 2020
FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 4 May 2020
CytoSorbents Promotes Vincent J. Capponi to President
Devices Personnel
 HSMN NewsFeed - 27 Apr 2020
Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer
Devices Personnel
 HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 13 Apr 2020
U.S. FDA Grants CytoSorb(R) Emergency Use Authorization for Use in Patients with COVID-19 Infection
Devices FDA
 HSMN NewsFeed - 31 Mar 2020
CytoSorb(R) Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care
Devices Regulatory
 HSMN NewsFeed - 30 Mar 2020
Lilly's Taltz(R) (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Mar 2020
CytRx Corporation Provides Update on Management Change
Biopharmaceuticals Oncology Neurology Personnel
 HSMN NewsFeed - 4 Mar 2020
Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma Group for Development and Commercialization of Novel Immunocytokine for the Treatment of B-Cell Lymphomas in China/Asia
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Feb 2020
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Feb 2020
Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Jan 2020
CytoSorb(R) is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.
Devices Regulatory Product Launch
 HSMN NewsFeed - 27 Jan 2020
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Jan 2020
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 9 Jan 2020
Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 20 Nov 2019
Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz(R) (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2019
CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom
Devices
 HSMN NewsFeed - 3 Oct 2019
New Head-to-Head Data Show Taltz(R) (ixekizumab) Superiority versus TREMFYA(R) (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 30 Sep 2019
Arix Bioscience plc: Arix Co-leads EUR 20 Million Series A Investment Round in STipe Therapeutics
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Aug 2019
PIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Aug 2019
Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Aug 2019
Torque Expands Leadership Team with Appointment of Sok Cheng Soh as CFO and Ana Radeljevic as VP, Head of Business Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 19 Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Jun 2019
FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jun 2019
Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2019
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz(R) (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 6 Jun 2019
Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 24 Apr 2019
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Apr 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 1 Apr 2019
OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO(TM) in Refractory Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Mar 2019
Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor
Devices Regulatory Distribution
 HSMN NewsFeed - 1 Mar 2019
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 1 Feb 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Jan 2019
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jan 2019
European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Dec 2018
OncoSec Announces Appointment Of Joon Kim, J.D., To Board Of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Dec 2018
Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Nov 2018
FDA Approves Gamifant(R) (emapalumab), the First and Only Treatment for Primary Haemophagocytic Lymphohistiocytosis (HLH)
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Nov 2018
OncoSec Appoints Robert Ward to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Nov 2018
Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Nov 2018
Torque Announces Appointment of Immunotherapy Pioneer F. Stephen Hodi, MD, to Scientific Advisory Board and Alex Bruni as COO/ CFO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Sep 2018
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 12 Sep 2018
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Sep 2018
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz(R) and Tremfya(R) in Patients with Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals
 HSMN NewsFeed - 4 Sep 2018
OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 29 Aug 2018
European Commission Approves BLINCYTO(R) (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Aug 2018
OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Aug 2018
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 1 Aug 2018
IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Jul 2018
OncoSec Appoints Robert W. Ashworth, Ph.D. as Vice President, Regulatory
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Jul 2018
Torque Appoints James Mullen as Chairman of Board of Directors, Maykin Ho, PhD, as Strategic Advisor to the Board of Directors, and Mario Sznol, MD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Jul 2018
Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 12 Jul 2018
Synthorx Expands Leadership Team with Three Key Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jun 2018
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
Biopharmaceuticals
 HSMN NewsFeed - 28 Jun 2018
Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
Biopharmaceuticals Generics
 HSMN NewsFeed - 30 Apr 2018
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin(TM) Cytokines
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 10 Apr 2018
TCR2 Therapeutics Appoints Leading Biotech Analyst Ian Somaiya as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Mar 2018
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 14 Mar 2018
Torque Appoints John Hohneker, MD, to Board of Directors and Marcela Maus, MD, PhD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Mar 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Mar 2018
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Mar 2018
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Feb 2018
AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 13 Feb 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals
 HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jan 2018
Novartis new data reinforces superiority of Cosentyx(R) versus Stelara(R) in achieving skin clearance for psoriasis patients
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Jan 2018
Enterome Raises €32 Million ($38.5 Million) in a Series D Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 20 Dec 2017
ORIC Has Appointed Rich Heyman, PhD as Acting Chief Executive Officer and Leonard Reyno, MD as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2017
Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 6 Dec 2017
Bioniz Therapeutics Appoints Graham Cooper to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2017
Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2017
Dermavant Sciences Appoints Vince Ippolito as President and Chief Operating Officer
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 4 Sep 2017
Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 14 Aug 2017
Synthorx Appoints Marcos Milla, Ph.D. as Senior Vice President of Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jul 2017
eFFECTOR Therapeutics Completes $38.6 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 17 Jul 2017
Medicenna Bolsters Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jul 2017
Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant(R) (baricitinib) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Jun 2017
EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for the First-Line Treatment of Advanced Renal Cell Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Jun 2017
EULAR 2017: Lilly's Taltz(R) (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
Biopharmaceuticals
 HSMN NewsFeed - 16 Jun 2017
New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2017
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 14 Apr 2017
U.S. FDA Issues Complete Response Letter for Baricitinib
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Apr 2017
NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 28 Mar 2017
Sanofi and Regeneron Announce FDA Approval of Dupixent(R) (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 28 Mar 2017
Akcea Therapeutics Announces Three Additions to Board of Directors
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 21 Mar 2017
Eyevensys Appoints Leading Life Sciences Executive and Ophthalmology Expert Dr. Garth Cumberlidge as Chairman
Biopharmaceuticals Devices Ophthalmology Personnel
 HSMN NewsFeed - 2 Mar 2017
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Feb 2017
European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Feb 2017
GSK Consumer Healthcare Launches FLONASE(R) Sensimist(TM) Allergy Relief Nationwide
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 19 Dec 2016
Northern Biologics, Mosaic Biomedicals Execute Transformative Deal
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 16 Dec 2016
Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 8 Dec 2016
Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent(R) (dupilumab) Accepted for Review by the EMA
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 7 Dec 2016
CytoSorb(R) Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany
Devices Reimbursement
 HSMN NewsFeed - 7 Dec 2016
Neovacs obtains FDA “Fast Track” designation for IFNα Kinoid in Lupus (SLE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Nov 2016
First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb(R)
Devices
 HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Oct 2016
Allergan Successfully Completes Vitae Tender Offer
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 7 Oct 2016
Rigel Expands Leadership Team in Research and Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2016
Allergan plc Enters Into Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 26 Sep 2016
Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 15 Sep 2016
Eyevensys Announces Series A Extension Bringing Total Capital Raised to €9 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 18 Aug 2016
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Aug 2016
FDA Approves FLONASE(R) Sensimist(TM) Allergy Relief
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Aug 2016
Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 25 Jul 2016
MiMedx Announces Nationwide Launch of New Ambient Temperature Version of OrthoFlo
Devices Regenerative Medicine Product Launch
 HSMN NewsFeed - 13 Jul 2016
CytoSorbents Teams with Medial and Meditrade to Bring CytoSorb(R) to Hungary, Czech Republic, Slovakia, and Poland
Devices Distribution
 HSMN NewsFeed - 12 Jul 2016
FDA Approves Shire’s Xiidra(TM) (lifitegrast ophthalmic solution) 5% – The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 18 May 2016
CytoSorb(R) Achieves Final Product Registration in Russia
Devices Distribution
 HSMN NewsFeed - 3 May 2016
Bioniz Therapeutics Appoints Fredrik Wiklund as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Mar 2016
Lion Biotechnologies Names Michael T. Lotze Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 11 Mar 2016
Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 29 Feb 2016
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
Biopharmaceuticals
 HSMN NewsFeed - 26 Feb 2016
Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Feb 2016
Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Feb 2016
Phase 3 Study of BLINCYTO(R) (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Amgen's BLINCYTO(R) (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Nov 2015
Jounce Therapeutics Appoints Elizabeth Trehu, M.D., to Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Sep 2015
Amgen To Acquire Privately-Held Dezima Pharma
Biopharmaceuticals Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 15 Sep 2015
Molecular Response Appoints the Former Head of Translational Medicine Oncology at MedImmune/AstraZeneca, Brett Hall, Ph.D., as Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 20 Aug 2015
Alder BioPharmaceuticals Appoints Paul B. Cleveland to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Aug 2015
Immunomedics Appoints Arthur S. Kirsch as Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Aug 2015
Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research & Development Expert, To Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Jun 2015
ViraTherapeutics Raises €3.6 Million in the First Closing of a Series A Financing Round to Advance its Novel Oncolytic Virus Platform
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 21 May 2015
Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 25 Nov 2014
Eleven Biotherapeutics Announces Additional Financing of $20 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 1 Aug 2014
European Commission Grants Orphan Drug Designation to Soliris(R) (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Jul 2014
AMNIOX(R) Medical Announces Initiation of Prospective, Randomized, Controlled Clinical Study of Chronic Wounds
Regenerative Medicine Wound Care
 HSMN NewsFeed - 29 May 2014
Aduro Announces License Agreement with Johnson & Johnson Innovation for Novel Immunotherapies for Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 19 May 2014
Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 May 2014
Gemmus Pharma Closes $3.3M Series B Funding to Develop Superior Flu Drug
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Mar 2014
Oculus Innovative Sciences Announces Appointment of Sharon Barbari to Its Board of Directors
Devices Wound Care Personnel
 HSMN NewsFeed - 18 Mar 2014
Immune Design Appoints Franklin M. Berger to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Mar 2014
Immune Design Appoints William Ringo to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Feb 2014
InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)
Biopharmaceuticals
 HSMN NewsFeed - 7 Feb 2014
Covis Pharmaceuticals Announces Its New Expanded Dosage Options of LANOXIN(R) for Cardiac Patients With Mild-to-Moderate Heart Failure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Jan 2014
Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Dec 2013
CytoSorbents Provides Clinical Update on CytoSorb Dosing Study
Devices
 HSMN NewsFeed - 19 Dec 2013
Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 13 Dec 2013
Neumedicines Presents HemaMax(TM) Clinical Data at the ASH Conference
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2013
OncoSec Medical Announces Hire of Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Nov 2013
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Biopharmaceuticals
 HSMN NewsFeed - 11 Nov 2013
Horizon Pharma and Mundipharma Sign Exclusive Agreement to Commercialize LODOTRA(R) in the Middle East and Africa
Biopharmaceuticals Distribution
 HSMN NewsFeed - 7 Nov 2013
ImmunGene Raises $9 Million in Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Oct 2013
Immune Design Raises Up to $49 Million Series C Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 30 Oct 2013
U.S. Army Rangers Initiate Groundbreaking Study on Wireless Microcurrent Generating Wound Dressing for Acute Wounds
Devices Wound Care
 HSMN NewsFeed - 24 Oct 2013
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Sep 2013
Immune Design Appoints Richard T. Kenney, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Aug 2013
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jul 2013
Pfizer Provides Update on Global Regulatory Approvals and Launches of XELJANZ(R) (tofacitinib citrate) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Jul 2013
Idera Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2013
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
Biopharmaceuticals
 HSMN NewsFeed - 8 Apr 2013
CytoSorbents Announces Trauma Advisory Board
Devices Personnel
 HSMN NewsFeed - 18 Mar 2013
Labrys Biologics Announces Key Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Nov 2012
Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
Biopharmaceuticals Wound Care Orthopaedic Acquisitions
 HSMN NewsFeed - 14 Nov 2012
OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Nov 2012
Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Oct 2012
OncoSec Receives CE Mark for Its Electroporation Device
Devices Drug Delivery Oncology Regulatory
 HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2012
DERMAGRAFT(R) Approved in Canada for Treatment of Diabetic Foot Ulcers
Devices Wound Care Regulatory
 HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Jun 2012
CytoSorbents Appoints Dr. Christian Steiner as VP of Sales and Marketing and Hires Core Sales Force That Marks the Official Launch of CytoSorb(R) in Germany
Devices Personnel
 HSMN NewsFeed - 23 Apr 2012
OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
Devices Drug Delivery Oncology
 HSMN NewsFeed - 28 Mar 2012
Bristol-Myers Squibb and Meso Scale Discovery Enter Agreement to Develop Diagnostic Assays for Alzheimer’s Disease
Diagnostics Neurology
 HSMN NewsFeed - 12 Mar 2012
Organogenesis Inc. Announces FDA Approval of GINTUIT(TM) for Oral Soft Tissue Regeneration
Regenerative Medicine Wound Care FDA
 HSMN NewsFeed - 29 Feb 2012
Abbott and Galapagos Announce Global Collaboration for Novel Oral Therapy, GLPG0634, in Phase II to Treat Autoimmune Diseases
Biopharmaceuticals
 HSMN NewsFeed - 9 Dec 2011
Immunomedics Creates Targeted Therapeutics for Solid Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2011
InterMune Announces Launch of Esbriet(R) (pirfenidone) in Germany
Biopharmaceuticals
 HSMN NewsFeed - 8 Sep 2011
Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 18 Jul 2011
SARcode Bioscience Completes $44 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Jul 2011
Coronado Biosciences Closes $25.8M in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Jun 2011
XOMA Appoints Paul Rubin, M.D. as Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2011
Pfizer Announces Top-Line Results Of Final Two Pivotal Phase 3 Trials Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 3 Mar 2011
InterMune Receives European Union Approval for Esbriet(R) (pirfenidone)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Feb 2011
Omni Bio Pharmaceutical Realigns Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Feb 2011
Cytokinetics Announces Changes to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
FDA Grants Supplemental Approval for ACTEMRA(R) (tocilizumab)
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Oct 2010
Exelixis Licenses Programs to Bristol-Myers Squibb Company
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Oct 2010
New Data Demonstrate Treatment With STELARA(R) (Black Triangle Drug) (ustekinumab) Results in Sustained Improvements in Psoriasis Severity and Quality of Life up to Three Years
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 7 Sep 2010
Bristol-Myers Squibb to Acquire ZymoGenetics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Jul 2010
Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA(R) Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2010
Galera Therapeutics Secures Funding for New Cancer Treatment
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 7 Jun 2010
Cytheris Closes 12 Million ($15 Million) Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 May 2010
STELARA(TM) Significantly Improves Symptoms of Depression, Anxiety and Health-Related Quality of Life in Patients With Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 16 Mar 2010
Genentech Submits Supplemental Biologics License Application for ACTEMRA(R) (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Mar 2010
Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 Feb 2010
Eleven Biotherapeutics Completes $35 Million Series A Funding to Advance Pipeline of Innovative Protein-Based Therapeutics
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Jan 2010
STELARA(TM) (ustekinumab) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 9 Jan 2010
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Nov 2009
MDRNA Expands RNAi Bladder Cancer Program With the Vancouver Prostate Centre
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 11 Nov 2009
Altair Therapeutics Secures $17 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Sep 2009
Janssen-Cilag's STELARA(R) (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 1 Sep 2009
Multiple Presentations at the European Society of Cardiology Congress Document EECP Promotes Coronary Collateral Flow Leading to Sustained Clinical Improvement
Devices Cardiology
 HSMN NewsFeed - 20 Aug 2009
Sutro Biopharma Announces Additions to Board of Directors and Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Aug 2009
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jul 2009
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jun 2009
BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Jun 2009
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
Regenerative Medicine
 HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 26 May 2009
Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2009
Altair Therapeutics Appoints Dr. Joel Martin President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 May 2009
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Apr 2009
Synageva BioPharma Announces $30 Million Equity Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Mar 2009
Provenance Biopharmaceuticals Corp. Announces License Agreement with Merck Serono for the Development and Commercialization of Novel Immunocytokine for the Treatment of Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Jan 2009
Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2009
TOPIGEN Pharmaceuticals Reports Phase 2 Results of TPI ASM8 in Asthma Patients
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2008
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2008
IDM Pharma Receives Recommendation for Approval of Mifamurtide (MEPACT(R), L-MTP-PE) for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicinal Products for Human Use (CHMP)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Oct 2008
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Biopharmaceuticals
 HSMN NewsFeed - 9 Oct 2008
EpiCept Receives Ceplene(R) Marketing Approval in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Sep 2008
Findings From Landmark Study Show Ustekinumab Demonstrated Superior Efficacy to Enbrel(R) (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 16 Sep 2008
Cytokinetics Announces Strategic Realignment of Workforce and Operations
Biopharmaceuticals
 HSMN NewsFeed - 15 Sep 2008
EpiCept Amends DURECT Bupivacaine Patch Licensing Agreement
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 3 Sep 2008
Wound Management Technologies, Inc. Announces Agreement with Dr. Leland Shapiro, MD
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 3 Sep 2008
DiaKine Therapeutics Announces Financing and New Board Member
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 4 Aug 2008
Expression Genetics Inc., Specializing in DNA/RNAi Delivery and Therapeutics, Completes $12M Series B Financing
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 4 Aug 2008
Pluristem Appoints Ms. Chaya Mazouz Clinical Operations Director
Regenerative Medicine Personnel
 HSMN NewsFeed - 22 Jul 2008
PhiloGene, Inc. Announces that VEGFb(TM) has been Granted Orphan Drug Designation by the FDA for the Treatment of Advanced Melanoma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 30 Jun 2008
Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 17 Jun 2008
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 13 Jun 2008
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Biopharmaceuticals
 HSMN NewsFeed - 10 Jun 2008
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Biopharmaceuticals
 HSMN NewsFeed - 28 May 2008
ADVEXIN(R) Improves Survival in Recurrent, Refractory Head and Neck Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2008
American Academy of Dermatology Issues New Guidelines for the Management of Psoriasis and Psoriatic Arthritis
Dermatology
 HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 12 May 2008
Pipex Pharmaceuticals Receives FDA Orphan Drug Designation for Oral TTM for Idiopathic Pulmonary Fibrosis (IPF)
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Apr 2008
FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 22 Apr 2008
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 21 Apr 2008
InterMune Announces Progress on Pirfenidone in IPF
Biopharmaceuticals
 HSMN NewsFeed - 14 Apr 2008
Vasogen Announces Implementation of Strategic Restructuring Plan
Biopharmaceuticals
 HSMN NewsFeed - 20 Mar 2008
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
Biopharmaceuticals
 HSMN NewsFeed - 4 Mar 2008
Pluristem Submits Pre-IND Application in Germany to Initiate Clinical Trials of PLX-PAD for Peripheral Artery Disease
Regenerative Medicine Regulatory
 HSMN NewsFeed - 4 Mar 2008
UCB: Early Data on Cimzia(R) from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 25 Feb 2008
Marillion Pharmaceuticals and Cytokine PharmaSciences Announce License Agreement for Xerostomia Treatment
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Feb 2008
VLST Corporation Announces Board and Executive Management Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2008
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Feb 2008
Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
Devices Wound Care
 HSMN NewsFeed - 11 Feb 2008
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 4 Feb 2008
IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Feb 2008
MediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Jan 2008
Pipex Pharmaceuticals Provides Update on COPREXA (Oral Tetrathiomolybdate) New Drug Application
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Jan 2008
The Aethlon Hemopurifier(R) Proves Effective in Capturing Bird Flu Virus
Devices
 HSMN NewsFeed - 9 Jan 2008
Ortec Shareholders Approve Corporate Name Change to Forticell Bioscience, Inc.
Regenerative Medicine Wound Care
 HSMN NewsFeed - 8 Jan 2008
Pluristem Announces Second Clinical Indication Revascularization Effect After PLX-PAD Therapy
Regenerative Medicine
 HSMN NewsFeed - 20 Dec 2007
Antisoma opens US Headquarters in Princeton, New Jersey
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2007
Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects TRIOLEX(TM) (HE3286) as a Next-Generation Oral Anti-Inflammatory Drug Candidate
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2007
Introgen Plans to Expand Biomarker Database in Phase 3 Trials and File BLA and MAA for ADVEXIN in Advanced Head and Neck Cancer in First Half of 2008
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2007
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Biopharmaceuticals Licensing Gastroenterology
 HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine
 HSMN NewsFeed - 5 Dec 2007
Amarin Signs Agreement to Acquire Ester Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 4 Dec 2007
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 27 Nov 2007
Introgen's ADVEXIN Advances as Marketing Authorization Application is Accepted for Review in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Nov 2007
Gendux Announces Acceptance of Its ADVEXIN Marketing Authorization Application for Review by the EMEA
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Nov 2007
InterMune Buys Out License Agreement for Pirfenidone
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Nov 2007
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Nov 2007
The Aethlon Hemopurifier(R) Reverses Immune Suppression in Cancer
Devices Oncology
 HSMN NewsFeed - 16 Nov 2007
UCB to Appeal European Negative Opinion on CIMZIA(R) for the Treatment of Patients with Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 15 Nov 2007
Introgen Therapeutics Highlights Summary ADVEXIN Data at the Third International Workshop on Mutant p53 and the Symposium on Li-Fraumeni Syndrome
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2007
Protox collaborates with BrainLAB for Brain Cancer Program
Devices Neurosurgery
 HSMN NewsFeed - 13 Nov 2007
Introgen and Gendux Submit First Marketing Authorization Application for ADVEXIN
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Nov 2007
Lodotra(TM) Shows a Sustained Reduction of Morning Stiffness in Patients with Rheumatoid Arthritis Treated with Lodotra(TM) for 12 Months
Biopharmaceuticals
 HSMN NewsFeed - 15 Oct 2007
Pipex Pharmaceuticals Appoints David A. Newsome, M.D. as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Oct 2007
ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Oct 2007
Nitec Pharma Expands Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2007
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 27 Sep 2007
Introgen Presents Biomarker Data Demonstrating Abnormal p53 Predicts ADVEXIN Efficacy in Head and Neck, Lung, Prostate and Li-Fraumeni Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2007
Pipex Pharmaceuticals Plans November NDA Filing for COPREXA Based on Pre-NDA Meetings With FDA
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Sep 2007
Teva Provides Update on Edratide for Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2007
Vasogen Plans Confirmatory Study of Celacade(TM) in Chronic Heart Failure to Support U.S. Regulatory Approval
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 12 Sep 2007
Innocoll Enters Into Collaboration With TGR Biosciences for Development of a Novel Wound Healing Product
Biopharmaceuticals Drug Delivery Wound Care
 HSMN NewsFeed - 3 Sep 2007
Nitec Pharma AG Announces Appointments of CEO & CFO in Preparation for Launch of Lodotra(R)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2007
IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Devices Oncology FDA
 HSMN NewsFeed - 13 Aug 2007
Avigen Initiates U.S. Clinical Development for AV411
Biopharmaceuticals
 HSMN NewsFeed - 30 Jul 2007
MedaSorb to Pursue 6 Billion Dollar Sepsis Market in Europe
Devices Regulatory
 HSMN NewsFeed - 25 Jul 2007
Fourth ACTEMRA(TM) (tocilizumab) Phase III Study Demonstrates Significant Clinical Benefit in RA Patients
Biopharmaceuticals
 HSMN NewsFeed - 18 Jul 2007
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Jul 2007
Aethlon Medical Announces Cancer Treatment Discovery
Devices Oncology
 HSMN NewsFeed - 11 Jul 2007
Ortec International: Dr. Costa Papastephanou Appointed CEO
Regenerative Medicine Wound Care Personnel
 HSMN NewsFeed - 10 Jul 2007
ACTEMRA(TM) (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Jun 2007
Cytokinetics Announces Second Extension of Research Term Under Collaboration With GlaxoSmithKline
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jun 2007
Rexahn Pharmaceuticals, Inc. Appoints Dr. Freddie Ann Hoffman to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jun 2007
Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
ACTEMRA(TM) (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
Biopharmaceuticals
 HSMN NewsFeed - 12 Jun 2007
CEL-SCI Receives US FDA Orphan Drug Designation for Its Cancer Drug Multikine(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Survival Benefit Demonstrated in Placebo-Controlled Trial in Patients with Refractory Non-Small Cell Lung Cancer Treated with Agennix's Oral Talactoferrin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
Introgen's ADVEXIN Demonstrates Clinical Benefit in Inherited Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2007
UCB Presents Long-Term CIMZIA(TM) Data in Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 16 May 2007
CollaGenex Pharmaceuticals and QuatRx Pharmaceuticals Announce Agreement for the Development and Commercialization of Becocalcidiol
Biopharmaceuticals Dermatology Licensing
 HSMN NewsFeed - 14 May 2007
Former Immunex Management Team Chosen to Head-Up CTI Subsidiary Aequus BioPharma, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 May 2007
FDA Advisory Committee Reviews Data on IDM Pharma's Junovan(TM) (mifamurtide) for Treatment of Osteosarcoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 May 2007
AEterna Zentaris Bolsters Management Team with Two Key Positions Named
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 May 2007
CollaGenex Pharmaceuticals Discontinues 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 May 2007
Critical Therapeutics' Co-Promotion Partner, DEY, L.P., Launches U.S. Sales and Marketing of ZYFLO(R) for Asthma
Biopharmaceuticals
 HSMN NewsFeed - 2 May 2007
CollaGenex Pharmaceuticals Provides Update on 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 30 Apr 2007
Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory Dose Doxycycline for the Treatment of Rosacea
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 24 Apr 2007
New TNS(R) Serum From SkinMedica(R) Exclusively Applied Through HydraFacial MD(TM) by Edge Systems
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 23 Apr 2007
CollaGenex Pharmaceuticals Provides Update on Examination of Incyclinide Patent Application
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 18 Apr 2007
Pipex Pharmaceuticals Appoints Kay E. Stremler, Ph.D. as Vice President of Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Apr 2007
Vasogen and Grupo Ferrer Form Collaboration to Commercialize Celacade(TM) in the European Union
Biopharmaceuticals Devices Cardiology
 HSMN NewsFeed - 14 Apr 2007
KCI Investigators Present Breast Cancer Findings
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2007
ARIAD files claim against Amgen and Wyeth Alleging Infringement of NF-(kappa)B Patent by Enbrel(R) and Kineret(R)
Biopharmaceuticals Litigation
 HSMN NewsFeed - 12 Apr 2007
XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 4 Apr 2007
Protemix Raises US$14.5 Million in First Close of Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 29 Mar 2007
Cameron Macdonald Appointed Managing Director of Controlled Therapeutics (Scotland) Limited
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2007
MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Mar 2007
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and Rheumatoid Arthritis in the US
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 20 Mar 2007
Aethlon Medical Files Cancer Treatment Patent
Devices Oncology
 HSMN NewsFeed - 14 Mar 2007
Tragara Pharmaceuticals, Inc. Announces Corporate Launch and Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Mar 2007
Critical Therapeutics and DEY, L.P. Enter into Co-Promotion Agreement for Respiratory Care Products
Biopharmaceuticals
 HSMN NewsFeed - 26 Feb 2007
Ortec Initiates Premarket Approval (PMA) Application Filing Seeking Approval for OrCel(R) in Treating Venous Leg Ulcers
Regenerative Medicine Wound Care FDA
 HSMN NewsFeed - 12 Feb 2007
Cell Therapeutics, Inc. (CTI) Spin-off to Use Proprietary Recombinant Genetic Technology to Develop Novel Biopharmaceuticals, Follow-on Biologics and to Deliver siRNA
Biopharmaceuticals
 HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
Positive Results of Phase 4 Clinical Study Evaluating Effects of Oracea(TM) (doxycycline, USP) Capsules, 40 mg, in Combination with MetroGel(R) (metronidazole gel), 1%, as Treatment for Rosacea Presented at Annual Meeting of the AAD
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 24 Jan 2007
Introgen Reports that INGN 241 in Combination with Avastin(R) Results in Complete Tumor Regression
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2007
Phase III ACTEMRA(TM) (tocilizumab) Study Results Demonstrate Significant Improvement in Signs and Symptoms of Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2007
Cytokinetics Announces Changes to its Executive Management Team and Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jan 2007
CEL-SCI Receives Green Light From FDA to Proceed With Phase III Cancer Study
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Jan 2007
Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
Regenerative Medicine Gastroenterology
 HSMN NewsFeed - 3 Jan 2007
Cytokinetics and Amgen Announce Strategic Alliance in Heart Failure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Dec 2006
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 26 Dec 2006
IDM Pharma Announces Acceptance for Review of the NDA for Junovan(TM) (Mifamurtide)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2006
Critical Therapeutics' Board of Directors Appoints Frank Thomas as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Dec 2006
CollaGenex Pharmaceuticals Signs License and Supply Agreement with MediGene for Marketing Rights to Oracea in EU and Certain Other Countries
Biopharmaceuticals Dermatology Licensing
 HSMN NewsFeed - 15 Dec 2006
Critical Therapeutics Announces NIH-Sponsored Study to Investigate the Efficacy Of ZYFLO(R) In Patients with Acute Exacerbations Of COPD
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2006
Jenken Biosciences Receives FDA Clearance for Phase II Trial of Lead Compound
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Dec 2006
Introgen Announces New Clinical Data Confirming ADVEXIN(R) Survival Benefit
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2006
Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals
 HSMN NewsFeed - 27 Nov 2006
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 27 Nov 2006
Genzyme Begins Phase 2 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Nov 2006
Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2006
Inovio Biomedical Grants VGX Pharmaceuticals License to Develop Novel Cancer Therapeutic
Biopharmaceuticals Oncology Drug Delivery Licensing
 HSMN NewsFeed - 13 Nov 2006
New Study Shows ACTEMRA(TM) (tocilizumab) Significantly Improves Remission Rates in Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Two-Year Data for ORENCIA(R) (abatacept) Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 6 Nov 2006
Pipex Therapeutics Merges With Sheffield Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Nov 2006
Cytokinetics Announces Presentations Relating to Clinical Trial Data on CK-1827452 and its Cardiac Myosin Activator Program at the 2006 Annual American Heart Association Scientific Sessions Meeting
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Nov 2006
Introgen Obtains Exclusive License to Therapies Combining Epidermal Growth Factor Drugs and Tumor Suppressor Genes
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2006
Introgen Therapeutics and Gendux AB Announce Agreement With European Medicines Agency to File for ADVEXIN Approval Under Exceptional Circumstance Rules
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Oct 2006
New Data Show CIMZIA(TM) (certolizumab pegol) May Improve Productivity in Work and with Daily Activities for People with Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Analysis Shows CIMZIA(TM) (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Efficacy Data Show CIMZIA(TM) (Certolizumab Pegol) Maintained Response and Remission in Crohn's Patients Previously Treated With Infliximab
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 Oct 2006
Introgen's ADVEXIN Molecular Targeted Therapy Is Active in Multiple Cancers; ADVEXIN Regulatory Program Advances
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Oct 2006
Hollis-Eden Pharmaceuticals Presents New Clinical Data That Support Use of NEUMUNE in Mitigating Acute Radiation Syndrome and Healthcare-Associated Infections
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2006
Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2006
Agennix Receives FDA Fast Track Designation for Talactoferrin Alfa in Non-Small Cell Lung Cancer and Diabetic Foot Ulcers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2006
Nephros Announces Positive Results of Clinical Study for Olpur MD190 Mid-Dilution Hemodiafiltration Filter
Devices
 HSMN NewsFeed - 4 Oct 2006
SkyePharma Reports Positive Phase III and EU Filing for Lodotra(TM)
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 29 Sep 2006
FDA Issues Approvable Letter to Ortec for Use of Cryopreserved OrCel(R) in Epidermolysis Bullosa Patients' Hand Reconstructions and Donor Sites
Regenerative Medicine FDA
 HSMN NewsFeed - 27 Sep 2006
FDA Approves REMICADE(R) for Treatment of Chronic Severe Plaque Psoriasis: Marks Major Milestone for Patients With High Disease Burden
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Sep 2006
Ortec Announces Positive Results in Confirmatory Venous Leg Ulcer Trial
Devices Wound Care Regenerative Medicine
 HSMN NewsFeed - 6 Sep 2006
Genzyme Begins Phase 3 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jul 2006
Cambrex and Ortec Submit to FDA a Humanitarian Device Exemption (HDE) for OrCel(R) to Treat Epidermolysis Bullosa Patients
Devices
 HSMN NewsFeed - 6 Jul 2006
Ortec Issues Update on Its Three Technology Platforms for Regenerative Medicine and Stem Cells
Regenerative Medicine
 HSMN NewsFeed - 27 Jun 2006
New Research Findings Published in National Academy of Sciences Journal Show Unique Promise of ONCONASE in the Prevention and Treatment of Mesothelioma and Lung Cancer Caused by Asbestos
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2006
Introgen's ADVEXIN p53 Therapy Demonstrates Clinical Benefit in Inherited Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2006
CollaGenex Pharmaceuticals Receives FDA Approval for Oracea(TM)
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 26 May 2006
Introgen to Announce Important New Clinical Data for ADVEXIN Cancer Therapy at Major Medical Meetings
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2006
CEL-SCI Presents Long-Term Survival Data With Its Anti-Cancer Drug Multikine(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2006
New CIMZIA (TM) Data from PRECiSE Program Reinforce Robust Efficacy in Once-Monthly Treatment of Crohn's Disease and Consistent Tolerability Profile
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 May 2006
Cyberonics Provides Update on Annual American Psychiatric Association Meeting Activities and Recent VNS Therapy Publications
Devices Neurology
 HSMN NewsFeed - 18 May 2006
Conor Medsystems Announces First Patient Treated with Dual-Drug Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 11 May 2006
Conor Medsystems Initiates RAPID Clinical Study for First Pimecrolimus Drug-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 10 May 2006
Theregen's Heart Patch of Living Cells Successfully Placed on First Patient
Devices Regenerative Medicine Cardiology
 HSMN NewsFeed - 9 May 2006
Gendux AB and Introgen Therapeutics File European Orphan Drug Designation for ADVEXIN
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 May 2006
Introgen's ADVEXIN p53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 277

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 277 additional stories matching:
Cytokine
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!